Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI5752 + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
MEDI5752 + nab-paclitaxel is a combination therapy under clinical investigation for advanced solid tumors. **MEDI5752** is a bispecific monoclonal antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), designed to enhance anti-tumor immunity by inhibiting two immune checkpoints simultaneously. **Nab-paclitaxel** (albumin-bound paclitaxel, marketed as Abraxane) is a solvent-free, nanoparticle albumin-bound formulation of paclitaxel, a cytotoxic agent that promotes microtubule assembly and inhibits disassembly, resulting in cell cycle arrest and apoptosis. Nab-paclitaxel is used as a chemotherapeutic backbone in various solid tumor regimens. This combination aims to leverage both immunotherapy and cytotoxic chemotherapy in treating advanced cancers, with ongoing early-phase studies for efficacy and safety in advanced solid tumors[3][5].
- Brand names
- Abraxane
- Other names
- albumin-bound paclitaxelABI-007ABI007ABI 007
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on MEDI5752 + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI5752 + nab-paclitaxel.